^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PRDX1 overexpression

i
Other names: PRDX1, Peroxiredoxin 1, Thioredoxin-Dependent Peroxide Reductase 2, Natural Killer Cell-Enhancing Factor A, Proliferation-Associated Gene Protein, Thioredoxin Peroxidase 2, Peroxiredoxin-1, NKEF-A, NKEFA, TDPX2, PAGA, PAGB, PAG, Epididymis Secretory Sperm Binding Protein, Thioredoxin-Dependent Peroxiredoxin 1, Natural Killer-Enhancing Factor A, Proliferation-Associated Gene A, MSP23, PRDX1, PRX1
Entrez ID:
Related biomarkers:
2ms
PRDX1 inhibits ferroptosis by binding to Cullin-3 as a molecular chaperone in colorectal cancer. (PubMed, Int J Biol Sci)
The inhibitory effects of PRDX1 knockdown on CRC could be attenuated by NRF2 activation or ferrostatin-1 administration in vivo. Collectively, these results provide a novel insight into the molecular chaperone activity of PRDX1 in promoting CRC progression through suppression of CUL3-mediated NRF2 degradation, suggesting PRDX1 Cys83 is a potential drug target in inhibiting CRC.
Journal
|
PRDX1 (Peroxiredoxin 1) • GPX4 (Glutathione Peroxidase 4)
|
PRDX1 overexpression
7ms
The interaction of PRDX1 with Cofilin promotes oral squamous cell carcinoma metastasis. (PubMed, Int J Cancer)
In clinical samples and mouse tongue cancer models, PRDX1 also increased lymph node metastasis of OSCC and was negatively correlated with the phosphorylation of Cofilin; PRDX1 also reduced the overall survival rate of OSCC patients. In summary, our study identified that PRDX1 may be a potential therapeutic target to inhibit OSCC metastasis.
Journal
|
PRDX1 (Peroxiredoxin 1)
|
PRDX1 overexpression
1year
Single cell and bulk transcriptome analysis identified oxidative stress response-related features of Hepatocellular Carcinoma. (PubMed, Front Cell Dev Biol)
High PRDX1 expression in HCC patients correlated with better sensitivity to immunotherapy agents such as sorafenib, IGF-1R inhibitor, and JAK inhibitor. In conclusion, our study unveiled variations in oxidative stress levels between non-tumor liver and HCC tissues. And we identified oxidative stress gene markers associated with hepatocarcinogenesis development, offering novel insights into the oxidative stress response mechanism in HCC.
Journal • IO biomarker
|
PD-L2 (Programmed Cell Death 1 Ligand 2) • PRDX1 (Peroxiredoxin 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
|
PRDX1 overexpression • LAIR1 expression
|
sorafenib
1year
Chronic exposure to low-dose deltamethrin can lead to colon tissue injury through PRDX1 inactivation-induced mitochondrial oxidative stress injury and gut microbial dysbiosis. (PubMed, Ecotoxicol Environ Saf)
Chronic exposure to DLM, even at small doses, can cause damage to the colon tissue, which cannot be ignored. The production and use of pesticides such as DLM should be strictly regulated during agricultural production.
Journal
|
PRDX1 (Peroxiredoxin 1)
|
PRDX1 overexpression
over1year
6-Shogaol prevents benzo (A) pyrene-exposed lung carcinogenesis via modulating PRDX1-associated oxidative stress, inflammation, and proliferation in mouse models. (PubMed, Environ Toxicol)
The histopathological studies also confirmed that 6-SGL effectively protected the cells with less damage. Thus, the study demonstrated that 6-SGL could be a potential phytochemical and act as a chemopreventive agent in BaP-induced lung cancer by enhancing PRDX1 expression.
Preclinical • Journal
|
CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • PRDX1 (Peroxiredoxin 1) • IL10 (Interleukin 10) • CCND2 (Cyclin D2) • PCNA (Proliferating cell nuclear antigen) • MAPK8 (Mitogen-activated protein kinase 8)
|
PRDX1 overexpression
over1year
Radiation induces IRAK1 expression to promote radioresistance by suppressing autophagic cell death via decreasing the ubiquitination of PRDX1 in glioma cells. (PubMed, Cell Death Dis)
Overexpression of PRDX1 reverses the radiotherapy sensitization effect of IRAK1 depletion by diminishing autophagic cell death. These results suggest the IRAK1-PRDX1 axis provides a potential therapeutic target for glioma patients.
Journal
|
PRDX1 (Peroxiredoxin 1) • STING (stimulator of interferon response cGAMP interactor 1) • FOXA2 (Forkhead Box A2) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1)
|
PRDX1 overexpression
2years
miR-375 suppresses the growth and metastasis of esophageal squamous cell carcinoma by targeting PRDX1. (PubMed, J Gastrointest Oncol)
Notably, over-expression of PRDX1 effectively counteracted the tumor-suppressing capabilities of miR-375. We demonstrated the antitumor effect of miR-375 on ESCC by targeting PRDX1 both in vitro and in vivo.
Journal
|
PRDX1 (Peroxiredoxin 1) • MIR375 (MicroRNA 375)
|
PRDX1 overexpression • miR-375 expression
2years
PRDX1 Influences The Occurrence and Progression of Liver Cancer by Inhibiting Mitochondrial Apoptosis Pathway. (PubMed, Cell J)
We propose that future works on PRDX1 inhibitors may act as a therapeutic candidate for treatment of liver cancer.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PRDX1 (Peroxiredoxin 1) • BCL2L11 (BCL2 Like 11) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • BAK1 (BCL2 Antagonist/Killer 1)
|
PRDX1 overexpression
almost3years
Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma. (PubMed, Neurochem Int)
PRDX1 expression exhibited negative correlation with DNA methylation. These results indicate that high expression of PRDX1, PRDX4 and PRDX6 is associated with poor outcome in gliomas.
Journal
|
PRDX1 (Peroxiredoxin 1) • PRDX2 (Peroxiredoxin 2)
|
PRDX1 overexpression
3years
PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. (PubMed, Cancer Immunol Res)
Finally, we generated PD-L1-CAR NK cells overexpressing PRDX1 that displayed potent antitumor activity against breast cancer cells under oxidative stress. These results demonstrate that hydrogen peroxide, at concentrations detected in the tumor microenvironment, suppresses NK-cell function and that genetic modification strategies can improve CAR-NK cells' resistance and potency against solid tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PRDX1 (Peroxiredoxin 1)
|
PD-L1 expression • PD-L1 overexpression • PRDX1 overexpression
over3years
Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. (PubMed, Cancer Lett)
Of note, downregulation of PRDX1 decreases the phosphorylation of AKT, thereby inducing cytoprotective autophagy and combinational use of NAT and chloroquine (CQ) achieves better anti-tumor efficacy. Moreover, NAT acts synergistically with sorafenib (SOR) in HCC suppression. Collectively, our study provides an important molecular basis for NAT-induced cell death and suggests that the antifungal NAT holds the potential to be repurposed as an anticancer drug for HCC treatment.
Journal
|
PRDX1 (Peroxiredoxin 1)
|
PRDX1 overexpression
|
sorafenib • chloroquine phosphate
over3years
Membrane bound Peroxiredoxin-1 serves as a biomarker for in vivo detection of sessile serrated adenomas. (PubMed, Antioxid Redox Signal)
RKO cells harboring the BRAFV600E mutation and human SSA specimens showed higher oxidative stress as well as elevated levels of Prdx1 on the cell membrane. Innovation and These results suggest that Prdx1 is overexpressed on the cell surface in the presence of oxidative stress, and can serve as an imaging biomarker for in vivo detection of SSAs.
Preclinical • Journal
|
PRDX1 (Peroxiredoxin 1)
|
BRAF V600E • BRAF V600 • PRDX1 overexpression
over3years
Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study. (PubMed, Dis Markers)
PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.
Retrospective data • Journal
|
PRDX1 (Peroxiredoxin 1)
|
PRDX1 overexpression